An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Verastem Oncology to Present at the Jefferies London Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Verastem Oncology (NASDAQ: VSTM) announced its participation in the Jefferies London Healthcare Conference, with an on-demand presentation available starting November 18, 2021, at 8:00 a.m. GMT (3:00 a.m. ET). A webcast will be accessible via the company's investor website, and an archived version will be available for 30 days. Verastem is dedicated to developing new cancer therapies, focusing on small molecule drugs that inhibit key signaling pathways critical for tumor growth and cell survival.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies London Healthcare Conference. The presentation will be made available for on-demand listening beginning Thursday, November 18, 2021 at 8:00 a.m. GMT (3:00 a.m. ET).
A webcast of the presentation will be available on investors section of the Company’s website at www.verastem.com. An archived presentation will be made available for 30 days.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com.